Zimbabwe has rejected a major American health deal valued at 367 million US dollars (272 million pounds) over five years due to the United States' insistence on confidential biological samples.
This rejection became public after a internal memorandum from December was leaked, revealing that President Emmerson Mnangagwa deemed the agreement was "skewed".
An official spokesperson has since clarified that the US was seeking biological samples for research and commercial purposes while was unwilling to guarantee the benefits from any future vaccines.
"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished over $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged further talks to secure a deal suitable to all parties so the country's critical HIV programme can continue.
Wider Implications
This rejection comes after a comparable situation in Kenya, where a high court suspended a similar deal with the US following legal challenges were raised about the security of Kenyans' health data.
Since returning to office recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government agreements to boost openness and accountability.
According to reports, 16 African countries have to date signed similar agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, without any corresponding promise of benefiting from any medical innovations – like new medicines or tests – that might result from that shared data," Mangwana explained.
"Put simply, our country would supply the basic resources for medical research without any assurance that the resulting innovations would be available to our citizens should a future disease outbreak arise."
Sovereignty and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining frameworks previously established through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme created to manage potential global health emergencies.
"This system is intended to guarantee that when a country contributes its data, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as opposition to America," he added.
"We are open to continued discussions with our US partners on how subsequent co-operation could be designed in a manner that honours the independence and dignity of both nations."
Health Experts Response
Medical experts stated it recognised the government's concerns, but recommended that negotiations need to persist given that much of the country's Aids initiatives depended on foreign aid.
"If technical issues arise, including those relating to data governance or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," it commented.
The situation emphasises the complex debate between receiving vital international aid and safeguarding national sovereignty in an ever more data-driven world.